At least we know that its not due to a capital issue.A decent poster on another share forum speculated that someone is taking a close look at IGR, could this be it?Who knows?
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%